https://www.selleckchem.com/pr....oducts/vafidemstat.h
3 weeks [95% CI 16.1-28.3]) vs continued IXE Q2W treatment (median not estimable, p0.0001); 67 (85%) patients vs 30 (38%) patients relapsed, respectively. Median time to re-achieving MDA on retreatment was 4.1 weeks (95% CI 4.1-4.3); 64 (96%) of 67 patients who relapsed with treatment withdrawal re-achieved MDA on retreatment. Safety was consistent with the known safety profile for ixekizumab. Continued ixekizumab therapy is superior to ixekizumab withdrawal in maintaining low disease activity in biologic-naive patients with PsA
Like
Comment
Share
